参考文献/References:
[1]Reutens AT, Atkins RC. Epidemiology of diabetic nephropathy[J]. Contrib Nephrol，2011, 170: 1-7.
[2]García-García PM, Getino-Melián MA, Domínguez-Pimentel V,et al.Inflammation in diabetic kidney disease[J].World J Diabetes,2014, 5(4): 431-443.
[3]Navarro-González JF, Mora-Fernández C, Muros de Fuentes M, et al. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy[J].Nat Rev Nephrol, 2011,7(6):327-340.
[4]King GL.The role of inflammatory cytokines in diabetes and its complications[J].J Periodontol,2008,79(8 Suppl): 1527-1534.?
[5]Navarro-González JF, Mora-Fernández C. The role of inflammatory cytokines in diabetic nephropathy[J].J Am Soc Nephrol, 2008,19(3): 433-442.?
[6]Lim AK, Tesch GH. Inflammation in diabetic nephropathy[J]. Mediators Inflamm,2012,2012: 146-154.?
[7]Wu CC, Sytwu HK, Lin YF. Cytokines in diabetic nephropathy[J]. Adv Clin Chem,2012,56: 55-74
[8]Schmid H, Boucherot A, Yasuda Y, et al. Modular activation of nuclear factor-κB transcriptional programs in human diabetic nephropathy[J].Diabetes,2006,55(11): 2993-3003.
[9]Nguyen D, Ping F, Mu W, et al. Macrophage accumulation in human progressive diabetic nephropathy[J].Nephrology(Carlton),2006, 11(3): 226-231.?
[10]Tesch GH. Macrophages and diabetic nephropathy[J].Semin Nephrol, 2010, 30(3): 290-301.
[11]Lee FT, Cao Z, Long DM, et al. Interactions between angiotensin Ⅱ and NF- κB-dependent pathways in modulating macrophage infiltration in experimental diabetic nephropathy[J]. J Am Soc Nephrol,2004, 15(8): 2139-2151.
[12]Han SY, Kim CH, Kim HS, et al. Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats[J]. J Am Soc Nephrol,2006,17(5): 1362-1372.
[13]Davis TM, Ting R, Best JD, et al. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study[J]. Diabetologia, 2011, 54(2): 280-290.?
[14]Kouroumichakis I, Papanas N, Zarogoulidis P, et al. Fibrates: therapeutic potential for diabetic nephropathy [J].Eur J Intern Med, 2012, 23(4): 309-316.?
[15]Matsushita Y, Ogawa D, Wada J, et al. Activation of peroxisome proliferator activated receptor delta inhibits streptozotocin induced diabetic nephropathy through anti-inflammatory mechanisms in mice[J].Diabetes,2011,60(3): 960-968.
[16]Gu L, Ni Z, Qian J, et al. Pravastatin inhibits carboxymethyllysine-induced monocyte chemoattractant protein 1 expression in podocytes via prevention of signalling events[J]. Nephron Exp Nephrol,2007,106(1): e1-e10.?
[17]Nakamura T, Sato E, Amaha M, et al. Ezetimibe reduces urinary albumin excretion in hypercholesterolaemic type 2 diabetes patients with microalbuminuria[J].J Int Med Res,2012,40(2): 798-803.
[18]Wu YG, Lin H, Qi XM, et al. Prevention of early renal injury by mycophenolate mofetil and its mechanism in experimental diabetes[J].Int Immunopharmacol,2006, 6(3): 445-453.
[19]Kodera R, Shikata K, Kataoka HU,et al. Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes[J]. Diabetologia, 2011, 54(4): 965-978.
[20]Navarro-González JF, Mora-Fernández C, Muros de Fuentes M, et al. Effect of pentoxifylline on renal function and urinary albumin excretion in patients with eiabetic kidney disease: the PREDIAN Trial[J]. J Am Soc Nephrol,2015,26(1):220-229.?
[21]Li JJ, Lee SH, Kim DK, et al. Colchicine attenuates inflammatory cell infiltration and extracellular matrix accumulation in diabetic nephropathy[J].Am J Physiol Renal Physiol, 2009,297(1): F200-F209.?
[22]Pan Y, Wang Y, Cai L, et al. Inhibition of high glucose-induced inflammatory response and macrophage infiltration by a novel curcumin derivative prevents renal injury in diabetic rats[J]. Br J Pharmacol,2012,166(3): 1169-1182.
[23]Lim AK, Ma FY, Nikolic-Paterson DJ, et al. Antibody blockade of c-fms suppresses the progression of inflammation and injury in early diabetic nephropathy in obese db/db mice[J].Diabetologia,2009, 52(8): 1669-1679.
[24]Navarro-González JF, Jarque A, Muros M, et al. Tumor necrosis factor-alpha as a therapeutic target for diabetic nephropathy[J]. Cytokine Growth Factor Rev, 2009,20(2): 165-173.
相似文献/References:
[1].2007年糖尿病新进展学习班将举办[J].国际内分泌代谢杂志,2007,(04):226.
[2]李英,段惠军.Raf/MEK/ERK信号转导通路在糖尿病肾病发生发展中的作用[J].国际内分泌代谢杂志,2007,(04):264.
[3]邵滢,王秋月.Mir-217/Sirt1通路与糖尿病肾病[J].国际内分泌代谢杂志,2015,(02):124.[doi:10.3760/cma.j.issn.1673-4157.2015.02.014]
Shao Ying,Wang Qiuyue..Mir-217 / Sirt1 pathway and diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(01):124.[doi:10.3760/cma.j.issn.1673-4157.2015.02.014]
[4]刘琦,周赛君,孟振兴,等.P2X7受体与糖尿病视网膜病变[J].国际内分泌代谢杂志,2015,(02):127.[doi:10.3760/cma.j.issn.1673-4157.2015.02.015]
Liu Qi,Zhou Saijun,Meng Zhenxing,et al.P2X7 receptor and diabetic retinopathy[J].International Journal of Endocrinology and Metabolism,2015,(01):127.[doi:10.3760/cma.j.issn.1673-4157.2015.02.015]
[5]王洁,何媛,于珮.糖尿病肾病的相关危险因素分析[J].国际内分泌代谢杂志,2015,(03):153.[doi:10.3760/cma.j.issn.1673-4157.2015.03.003]
Wang Jie*,He Yuan,Yu Pei..Risk factors of diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(01):153.[doi:10.3760/cma.j.issn.1673-4157.2015.03.003]
[6]任慧雯,王秋月.Epac-Rap1与糖尿病肾病[J].国际内分泌代谢杂志,2015,(03):170.[doi:10.3760/cma.j.issn.1673-4157.2015.03.007]
Ren Huiwen,Wang Qiuyue..Epac-Rap1 and diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(01):170.[doi:10.3760/cma.j.issn.1673-4157.2015.03.007]
[7]陈堃,刘超,陈国芳,等.糖尿病肾病诊断标志物研究进展[J].国际内分泌代谢杂志,2015,(03):176.[doi:10.3760/cma.j.issn.1673-4157.2015.03.009]
Chen Kun,Liu Chao,Chen Guofang,et al.Urinary biomarkers for diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(01):176.[doi:10.3760/cma.j.issn.1673-4157.2015.03.009]
[8]潘道延,沈洁,朱筱,等.利格列汀对2型糖尿病大鼠代谢性内毒素血症的影响[J].国际内分泌代谢杂志,2015,(04):230.[doi:10.3760/cma.j.issn.1673-4157.2015.04.004]
Pan Daoyan,Shen Jie,Zhu Xiao,et al.Effects of linagliptin on metabolic endotoxemia in type 2 diabetic rats[J].International Journal of Endocrinology and Metabolism,2015,(01):230.[doi:10.3760/cma.j.issn.1673-4157.2015.04.004]
[9]任慧雯,王秋月.Vasohibin-1与糖尿病肾病[J].国际内分泌代谢杂志,2015,(04):246.[doi:10.3760/cma.j.issn.1673-4157.2015.04.008]
Ren Huiwen,Wang Qiuyue..Vasohibin-1 and diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(01):246.[doi:10.3760/cma.j.issn.1673-4157.2015.04.008]
[10]安丽,王秋月.Visfatin与胰岛素抵抗及糖尿病肾病的发病机制[J].国际内分泌代谢杂志,2015,(04):248.[doi:10.3760/cma.j.issn.1673-4157.2015.04.009]
An Li,Wang Qiuyue..Visfatin in the pathogenesis of insulin resistance and diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(01):248.[doi:10.3760/cma.j.issn.1673-4157.2015.04.009]
[11]邵滢,王秋月.MiRNA-150与糖尿病肾病[J].国际内分泌代谢杂志,2015,(03):173.[doi:10.3760/cma.j.issn.1673-4157.2015.03.008]
Shao Ying,Wang Qiuyue..MiRNA-150 and diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(01):173.[doi:10.3760/cma.j.issn.1673-4157.2015.03.008]